Attana extends collaborative research agreement with leading US academic medical center for biomedical research
Attana can today announce that the collaborative research agreement with one of the leading academic medical centers in the US has been extended.
In March, Attana announced that a collaborative research agreement had been signed with one of the leading US academic medical centers within biomedical research, focusing on viruses and antibodies. Since then, Attana has installed an Attana CellTM 250 instrument, trained laboratory personnel, and provided application support services. Today, the parties have agreed to extend the collaboration into October. As previously communicated, this agreement may be mutually extended until the end of 2025.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com
tel: + 46 8 674 57 00
This is information that Attana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags: